A Reversal for Galectin Therapeutics, Inc. (GALT) Is Not Near. The Stock Rises Again

December 7, 2017 - By Marguerite Chambers

Investors sentiment decreased to 1.89 in 2017 Q2. Its down 0.36, from 2.25 in 2017Q1. It turned negative, as 3 investors sold Galectin Therapeutics, Inc. shares while 6 reduced holdings. 9 funds opened positions while 8 raised stakes. 3.37 million shares or 8.69% more from 3.10 million shares in 2017Q1 were reported.
17,104 are held by Goldman Sachs. Neuberger Berman Gp Limited Co reported 82,494 shares. Susquehanna Group Llp holds 0% or 85,346 shares. Sei Communications has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Morgan Stanley holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 108,488 shares. Deutsche Bank Ag holds 0% or 102 shares in its portfolio. Riggs Asset Managment holds 0% or 1,000 shares. Cetera Advisor Networks Ltd Liability Corporation invested in 0% or 15,721 shares. Salem Investment Counselors invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Stratos Wealth Partners Limited, Ohio-based fund reported 24,154 shares. Courage Cap Mngmt Lc has invested 0.16% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Dynamic Advisors Solutions Ltd stated it has 0.01% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Vanguard Gru owns 871,510 shares for 0% of their portfolio. Art Advsr Ltd Llc holds 0.01% or 45,843 shares. First Manhattan reported 1,667 shares stake.

The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) is a huge mover today! The stock increased 36.36% or $0.56 during the last trading session, reaching $2.1. About 4.74M shares traded or 1075.60% up from the average. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 62.09% since December 7, 2016 and is uptrending. It has outperformed by 45.39% the S&P500.
The move comes after 9 months positive chart setup for the $74.84 million company. It was reported on Dec, 7 by Barchart.com. We have $2.16 PT which if reached, will make NASDAQ:GALT worth $2.25 million more.

Analysts await Galectin Therapeutics, Inc. (NASDAQ:GALT) to report earnings on March, 27. They expect $-0.12 EPS, up 7.69 % or $0.01 from last year’s $-0.13 per share. After $-0.13 actual EPS reported by Galectin Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -7.69 % EPS growth.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics had 10 analyst reports since September 21, 2015 according to SRatingsIntel. TH Capital downgraded the stock to “Sell” rating in Wednesday, September 28 report. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Buy” rating by H.C. Wainwright on Monday, September 21. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Sell” rating by Roth Capital on Wednesday, September 28. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Buy” rating by H.C. Wainwright on Monday, March 28. The company was downgraded on Thursday, September 29 by H.C. Wainwright. H.C. Wainwright maintained Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Wednesday, June 14. H.C. Wainwright has “Buy” rating and $3.5000 target. FBR Capital downgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Monday, October 3. FBR Capital has “Mkt Perform” rating and $2 target. H.C. Wainwright upgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Thursday, March 30. H.C. Wainwright has “Buy” rating and $3.50 target.

More important recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Globenewswire.com which released: “Galectin Therapeutics CEO Peter G. Traber, MD Named Chair of the Anti-Fibrotic …” on November 13, 2017, also Marketwatch.com published article titled: “Galectin Therapeutics stock drops nearly 50% after negative trial results”, Nasdaq.com published: “Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options” on December 01, 2017. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) was released by: Seekingalpha.com and their article: “Galectin Therapeutics: Time To Exit” with publication date: December 06, 2017.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $74.84 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.